-
Posted by
Two Blokes May 1 -
Filed in
Stock
-
0 views
VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favorable, that could impact the performance of the stock.
